MLYS
Mineralys Therapeutics, Inc.NASDAQHealthcare$26.97+2.12%ClosedMarket Cap: $1.79B
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
3.52
P/S
0.00
EV/EBITDA
-10.21
DCF Value
$2.53
FCF Yield
-7.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-32.9%
ROA
-23.4%
ROIC
-26.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-32.2M | $-0.40 |
| FY 2025 | $0.00 | $-154.7M | $-2.29 |
| Q3 2025 | $0.00 | $-36.9M | $-0.52 |
| Q2 2025 | $0.00 | $-43.3M | $-0.66 |
Analyst Ratings
View AllB of A SecuritiesBuy
2026-03-13StifelBuy
2025-12-19HC Wainwright & Co.Buy
2025-11-12Wells FargoOverweight
2025-11-11Wells FargoOverweight
2025-09-11Trading Activity
Insider Trades
View AllCongleton Jondirector, officer: Chief Executive Officer
SellThu Apr 02
Karydas Daphnedirector
SellThu Apr 02
Karydas Daphnedirector
SellThu Apr 02
Congleton Jondirector, officer: Chief Executive Officer
SellThu Apr 02
Congleton Jondirector, officer: Chief Executive Officer
SellThu Apr 02
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.69
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.